In Vitro Diagnostics (IVD) Quality Control Market Size, Share & Trends Analysis Report By Product (Plasma-based Control, Serum-based Control & Whole Blood-based Control), By Applications (Hospitals, Laboratory, Research Institutes and Academics, Others), By End Use, By Region, and Segment Forecasts - 2035

In Vitro Diagnostics (IVD) Quality Control Market Overview

in vitro diagnostics (ivd) quality control market size was valued at USD 1308.68 million in 2025 and is poised to grow from USD 1368.23 million in 2026 to USD 1563.62 million by 2035, growing at a CAGR of 4.55% during the forecast period (2026-2035).

The In Vitro Diagnostics (IVD) Quality Control Market in 2026 is being shaped by increasing test complexity, wider adoption of automated analyzers, laboratory accreditation requirements, risk-based quality control planning, molecular diagnostics growth, and greater use of third-party controls. Serum-based Control is estimated to account for approximately 44% of Product Type demand because serum-like matrices are widely compatible with clinical chemistry, immunoassay, endocrine, cardiac marker, tumor marker, and specialty testing workflows. Plasma-based Control represents approximately 33%, while Whole Blood-based Control accounts for around 23%. By Application, Laboratory represents an estimated 43% of demand, Hospitals account for approximately 34%, Research Institutes and Academics contribute around 15%, and Others represent 8%. Quality programs increasingly use at least 2 or 3 control levels spanning normal and abnormal clinical concentrations, allowing laboratories to identify shifts, trends, reagent deterioration, calibration errors, and analyzer instability. Risk-based laboratory quality planning has also gained importance, with modern guidance encouraging each measuring system to be assessed according to method performance, clinical risk, operating environment, and the detectability of potential failures.

The United States remains one of the largest In Vitro Diagnostics (IVD) Quality Control Markets because of its extensive clinical laboratory network, high diagnostic testing volumes, regulatory oversight, accreditation requirements, advanced automation, and established use of third-party quality controls. North America is estimated to account for approximately 39% of global demand in 2026. Serum-based Control contributes around 45% of regional Product Type consumption, Plasma-based Control represents approximately 32%, and Whole Blood-based Control accounts for 23%. Laboratory represents approximately 42% of regional Applications, Hospitals contribute 36%, Research Institutes and Academics account for 14%, and Others represent around 8%. Modern U.S. laboratories increasingly use digital QC analytics to monitor assay performance continuously rather than reviewing results only after scheduled runs. Informatics platforms introduced during 2025 expanded real-time instrument and assay monitoring, automated result verification, connectivity across multiple analyzers, and concurrent multi-user access. Laboratory quality systems increasingly combine internal controls, calibration verification, proficiency testing, peer-group comparison, and Six Sigma metrics to improve analytical reliability.

• 

  Download Free sample to learn more about this report.

Key Findings

• Leading Product Type: Serum-based Control is estimated to hold approximately 44% market share because serum matrices support broad clinical chemistry, immunoassay, endocrine, cardiac, tumor-marker, and specialty diagnostic testing.
• Leading Application: Laboratory is estimated to account for approximately 43% of demand as high-throughput diagnostic centers require continuous internal quality control across chemistry, hematology, molecular, and immunodiagnostic assays.
• Leading Region: North America is estimated to hold approximately 39% market share, supported by stringent laboratory quality requirements, high testing volumes, automation, accreditation, and extensive third-party control adoption.
• Fastest Growing Region: Asia-Pacific is projected to expand at approximately 6.1% annually as laboratory automation, hospital diagnostics, molecular testing, accreditation, and healthcare infrastructure continue expanding.
• Technology Trend: Modern QC informatics platforms can connect multiple analyzers while supporting unlimited concurrent users, enabling real-time quality monitoring and centralized management of large laboratory networks.
• Market Driver: Molecular controls can demonstrate storage stability of up to approximately 36 months at minus 20 degrees Celsius, improving reliability across extended diagnostic quality-control programs.
• Competitive Landscape: One major automated sample-preparation platform has exceeded approximately 3,300 cumulative placements, reinforcing demand for standardized quality controls across increasingly automated molecular laboratories.
• Future Outlook: Risk-based QC frameworks increasingly evaluate at least 4 factors including analytical performance, laboratory environment, regulatory requirements, and clinical risk before establishing individualized control plans.

Latest Trends

Digital QC data management is one of the most important trends influencing the In Vitro Diagnostics (IVD) Quality Control Market in 2026. Laboratories increasingly replace manual spreadsheet-based review with connected systems that automatically capture control measurements from analyzers, compare performance against laboratory targets, identify shifts or trends, and maintain auditable histories. Modern QC connectivity can transfer information directly from diagnostic instruments into centralized software without interrupting the data stream to the laboratory information system. Automated import reduces manual transcription and can eliminate 1 major source of QC reporting error. Statistical monitoring increasingly combines Levey-Jennings charts, Westgard-type decision rules, peer-group comparison, coefficient-of-variation analysis, bias assessment, and Six Sigma performance metrics. Laboratories operating dozens of analyzers can therefore identify deteriorating assay performance more quickly than when every instrument is reviewed separately. Digital systems also support remote oversight, enabling centralized quality teams to review multiple sites and standardize control limits across hospital networks.

Third-party and molecular quality controls are another major trend. Manufacturer-independent controls allow laboratories to evaluate the complete analytical process without relying exclusively on material optimized by the instrument or reagent supplier. Molecular testing has increased this requirement because quality controls must challenge extraction, amplification, detection, and data interpretation. Stabilized nucleic-acid controls increasingly use protein-coated RNA or DNA constructs to create non-infectious materials resistant to nuclease degradation. Certain molecular control materials can remain stable for up to approximately 36 months at minus 20 degrees Celsius, 12 months at 4 degrees Celsius, and several months in selected plasma formulations. These characteristics improve lot consistency and reduce frequent replacement. Ready-to-use liquid controls are also expanding across blood gas, clinical chemistry, immunodiagnostics, and urinalysis because they minimize reconstitution steps. In high-throughput laboratories performing thousands of patient tests daily, eliminating even 1 manual preparation step from each QC cycle can improve workflow efficiency and reduce operator variability.

Market Dynamics

Driver

""Rising diagnostic complexity is increasing demand for continuous and independent quality verification.""

The strongest driver of the In Vitro Diagnostics (IVD) Quality Control Market is expansion in the number and complexity of diagnostic tests performed by Hospitals and Laboratory facilities. Modern analyzers can process hundreds or thousands of tests per hour, making undetected analytical error potentially more consequential than in low-volume manual testing environments. Laboratories therefore use multiple control levels to verify performance before releasing patient results. A typical quantitative assay may use 2 or 3 QC concentrations to evaluate performance across clinically relevant ranges. High-throughput laboratories can run these materials at the beginning of each analytical shift, after calibration, following reagent changes, and whenever performance concerns arise. Laboratory and Hospitals together represent approximately 77% of market demand, demonstrating how closely quality-control consumption follows routine patient-testing activity.

Regulatory and accreditation expectations provide another important driver. Risk-based quality planning increasingly requires laboratories to evaluate each measuring system in relation to analytical performance, clinical use, regulatory obligations, and the laboratory environment. A control strategy may therefore differ even when 2 laboratories use the same analyzer. Modern guidance also emphasizes continual review rather than treating a QC plan as static. Laboratories are expected to detect trends, investigate failures, document corrective action, and revise control procedures when risks change. These requirements support recurring demand for stable control materials, data-management software, calibration verification, and peer-group programs. Increased use of automated quality analytics also raises demand for controls with long lot stability because laboratories prefer comparable data across many months.

Restraint

""Control material costs and complex validation requirements can constrain smaller laboratory budgets.""

The main restraint is the recurring expense associated with internal controls, calibration verification, proficiency testing, software, and staff time. A laboratory operating 20 or more analyzers may need separate control materials for clinical chemistry, immunoassay, hematology, coagulation, blood gas, molecular diagnostics, and specialty assays. If each test family requires 2-3 control levels, the number of vials and lots managed annually can become substantial. Controls also have defined storage requirements, open-vial stability, expiration periods, and preparation procedures. Small laboratories with limited test volumes may find the cost per patient result significantly higher because they consume controls even when only a small number of patient samples are analyzed.

Matrix and commutability limitations also create restraints. A control material that performs well on 1 platform may not behave exactly like patient samples across every analytical method. Serum-based Control represents approximately 44% of Product Type demand because of broad compatibility, but certain assays require Plasma-based Control or Whole Blood-based Control to more closely mimic the clinical specimen. Molecular assays create an additional challenge because synthetic nucleic-acid controls may not reproduce every stage of real specimen processing unless they are designed as full-process controls. Laboratories therefore need careful verification before adopting a new material. This can require multiple days of testing, comparison with existing controls, target establishment, and documentation.

Opportunity

""Automation and multi-site laboratory networks create major opportunities for centralized QC management.""

The strongest opportunity is centralized digital quality control across hospital systems and reference laboratory networks. Large organizations can operate dozens of analyzers across multiple locations, making manual comparison difficult. Connected QC platforms can consolidate results from multiple instruments, apply standardized rules, generate alerts, and enable quality managers to review performance remotely. One modern informatics architecture supports multiple instrument connections and unlimited concurrent users, allowing large organizations to expand without assigning separate software access to each instrument. Centralized quality management can also help laboratories identify whether an abnormal result is specific to one analyzer or reflects a broader reagent-lot or method issue.

Molecular diagnostics creates another major opportunity. Nucleic-acid testing has expanded from specialist laboratories into routine hospital and clinical settings, increasing demand for controls that challenge extraction and amplification. Stabilized molecular controls can be used as extraction controls, process controls, positive controls, or reference materials. Certain armored RNA and DNA technologies use protein coatings to protect nucleic acid against degradation and can remain stable for up to 36 months under frozen storage. Custom multiplex controls provide additional opportunity because diagnostic manufacturers can combine several targets into 1 material. This reduces the number of separate vials laboratories need to handle and supports increasingly complex multiplex testing panels.

Challenge

""Maintaining consistent QC interpretation across diverse platforms remains operationally difficult.""

The principal challenge is ensuring that quality-control results are interpreted appropriately across different instruments, methods, reagent lots, laboratories, and clinical applications. A single control value cannot always be transferred directly between platforms because different assays may use distinct antibodies, calibrators, reaction chemistries, wavelengths, or mathematical algorithms. Laboratories therefore establish method-specific targets and acceptable ranges. When a new reagent lot is introduced, performance may need to be compared with the previous lot before routine patient testing. High-throughput facilities can conduct dozens of lot comparisons annually, making quality management a continuous operational activity.

Statistical interpretation presents another challenge. QC programs generate large quantities of numerical data, but excessive rules can create false rejection while insufficient rules may fail to detect clinically relevant analytical error. Laboratories may use several decision rules simultaneously, including limits based on 2 or 3 standard deviations, shifts across consecutive measurements, and trends over multiple control events. When more than 10 assays are monitored across several instruments, the number of possible alerts increases rapidly. Laboratories therefore need software capable of prioritizing meaningful deviations rather than overwhelming staff with warnings. Advanced analytics and Six Sigma approaches are increasingly used to tailor QC frequency and rule selection according to assay performance.

• 

  Download Free sample to learn more about this report.

Segmentation Analysis

By Types

Plasma-based Control: Plasma-based Control is estimated to account for approximately 33% market share and is widely used when assays are designed around plasma specimens or when anticoagulated matrices more closely represent patient samples. Applications can include coagulation-related testing, molecular diagnostics, immunodiagnostics, and selected chemistry assays. Plasma-based material can also support molecular control systems because nucleic-acid targets may be formulated within a human plasma background. Some stabilized molecular controls have demonstrated plasma stability lasting up to approximately 28 weeks at 4 degrees Celsius under selected formulations, improving usability across extended laboratory programs.

Serum-based Control: Serum-based Control leads with approximately 44% market share because serum is widely used across chemistry and immunoassay testing. Multi-analyte serum controls can consolidate dozens of analytes into 1 vial, reducing the number of separate materials required during each QC run. Commercial serum controls commonly provide 2 or 3 concentration levels so laboratories can assess performance at low, normal, and high ranges. Long lot availability is valuable because laboratories can maintain consistent statistical baselines for 12 months or longer without frequent target reassignment.

Whole Blood-based Control: Whole Blood-based Control represents approximately 23% market share and is particularly important in hematology, blood gas, point-of-care, and other testing where cellular or whole-blood characteristics influence analytical performance. Hematology controls may provide 3-part or 5-part differential evaluation, reticulocyte assessment, and additional cell-related measurements. Whole Blood-based Control requires more specialized stabilization because cells and hemoglobin-related characteristics change more readily than many serum analytes. This technical complexity supports comparatively high value per unit despite its smaller market share.

By Applications

Hospitals: Hospitals account for approximately 34% market share because hospital laboratories perform time-sensitive diagnostic testing across emergency care, intensive care, surgery, cardiology, oncology, infectious disease, and general medicine. Hospital laboratories can operate 24 hours per day and may run QC several times during a single day depending on test complexity and laboratory policy. Blood gas analyzers commonly use multiple control levels for daily quality verification, while chemistry and immunoassay systems can perform hundreds of assays from a single instrument platform.

Laboratory: Laboratory dominates with approximately 43% market share because independent reference laboratories and large diagnostic centers process high sample volumes and often maintain extensive analyzer fleets. These organizations benefit strongly from automated QC data management because they may operate 10, 20, or more instruments across different departments. Peer-group comparison is particularly valuable because high-volume facilities seek to benchmark analytical performance against thousands of comparable laboratories and instruments. Long-term QC data also support accreditation inspections and continuous improvement programs.

Research Institutes and Academics: Research Institutes and Academics represent approximately 15% market share. These facilities use control materials during assay development, translational research, biomarker validation, clinical studies, and method comparison. Research workflows may require customized concentrations or novel molecular targets unavailable in standard commercial control products. Custom control development therefore provides an important growth area. Academic laboratories may also use quality-control materials to train clinical laboratory scientists and evaluate new diagnostic technologies before routine implementation.

Others: Others account for approximately 8% market share and include point-of-care testing locations, physician-office laboratories, specialty clinics, diagnostic developers, proficiency-testing providers, and other users. Smaller sites increasingly need simplified ready-to-use controls because staff may have limited laboratory specialization. Certified analyzer programs introduced in 2025 specifically targeted clinics, physician-office laboratories, and hospitals with fewer than 100 beds, demonstrating growing attention to decentralized diagnostic testing and associated quality requirements.

• 

  Download Free sampleto learn more about this report.

Regional Outlook

North America

North America is estimated to lead the In Vitro Diagnostics (IVD) Quality Control Market with approximately 39% global share in 2026. Serum-based Control represents around 45% of regional Product Type demand, Plasma-based Control accounts for approximately 32%, and Whole Blood-based Control contributes around 23%. Laboratory represents approximately 42% of Applications, Hospitals contribute 36%, Research Institutes and Academics account for 14%, and Others represent approximately 8%. Quidel Corp., Bio-Techne, Alere, Inc., and Bio-Rad Laboratories, Inc. provide strong supplied-company representation from the United States.

The region benefits from advanced automation, stringent laboratory oversight, established accreditation programs, high testing volumes, and widespread use of independent control materials. Digital quality management is expanding rapidly. Real-time monitoring systems introduced during 2025 allow laboratories to connect multiple diagnostic analyzers, monitor instruments and assays continuously, automate result verification, and support unlimited concurrent users. North America also maintains a strong molecular diagnostics ecosystem, increasing demand for stabilized nucleic-acid controls and full-process materials. The region is expected to retain leadership through 2035 despite faster growth in Asia-Pacific.

Europe

Europe is estimated to account for approximately 27% of global In Vitro Diagnostics (IVD) Quality Control Market demand. Serum-based Control contributes around 43% of regional Product Type activity, Plasma-based Control represents 34%, and Whole Blood-based Control accounts for approximately 23%. Laboratory contributes around 44% of Applications, Hospitals account for 33%, Research Institutes and Academics represent 16%, and Others contribute approximately 7%. Qiagen N.V. provides supplied-company representation from the Netherlands.

European demand is supported by extensive clinical laboratory accreditation, adoption of quality-management standards, automation, molecular testing, and the transition to strengthened IVD regulatory requirements. Diagnostic laboratories increasingly need traceable documentation showing that analytical systems remain under control throughout routine operation. In 2025 and 2026, automated molecular laboratory development accelerated as new sample-preparation systems were introduced or prepared for launch. One established automated preparation platform had already exceeded approximately 3,300 cumulative placements, illustrating the scale of installed equipment requiring controls, calibration materials, and ongoing performance monitoring.

Asia-Pacific

Asia-Pacific is estimated to account for approximately 25% of global In Vitro Diagnostics (IVD) Quality Control Market demand and is projected to expand at around 6.1% annually. Serum-based Control accounts for approximately 42% of regional Product Type demand, Plasma-based Control represents 35%, and Whole Blood-based Control contributes around 23%. Laboratory contributes approximately 45% of Applications, Hospitals account for 34%, Research Institutes and Academics represent 14%, and Others contribute approximately 7%.

China, India, Japan, South Korea, Australia, and Southeast Asia are expanding diagnostic infrastructure and laboratory automation. Large urban reference laboratories increasingly process thousands of samples per day, creating demand for standardized internal QC and software-based performance review. Hospital networks are also expanding molecular and immunoassay testing. Asia-Pacific's faster growth reflects both increasing diagnostic volumes and gradual adoption of more formal accreditation and quality-management frameworks. The number of analyzers per laboratory is also rising, increasing demand for multi-analyte controls that reduce the number of separate QC materials required.

Middle East & Africa

Middle East & Africa is estimated to account for approximately 4% of global In Vitro Diagnostics (IVD) Quality Control Market demand. Serum-based Control represents around 43% of regional Product Type consumption, Plasma-based Control contributes 34%, and Whole Blood-based Control accounts for approximately 23%. Hospitals account for approximately 42% of Applications, Laboratory represents 36%, Research Institutes and Academics contribute 13%, and Others account for around 9%.

Saudi Arabia, the United Arab Emirates, South Africa, Egypt, and several other healthcare hubs are investing in laboratory modernization and centralized diagnostics. Large tertiary hospitals increasingly deploy automated analyzers comparable with systems used in North America and Europe. High-temperature logistics environments can increase the importance of stable control formulations and validated cold-chain management. Regional growth is expected to accelerate as laboratory accreditation expands and more testing moves from manual methods to fully automated analyzers capable of processing hundreds of samples per hour.

List of Top In Vitro Diagnostics (IVD) Quality Control Companies

• Quidel Corp. (U.S)
• Bio-Techne (U.S)
• Alere, Inc. (U.S)
• Qiagen N.V. (Netherland)
• Bio-Rad Laboratories, Inc. (U.S)

Top 2 Companies Market Share

Bio-Rad Laboratories, Inc.: Bio-Rad Laboratories, Inc. is estimated to hold approximately 16-19% competitive market share among major IVD quality-control suppliers, supported by extensive independent control materials, peer-group programs, QC data-management software, calibration verification, and laboratory informatics. Its modern QC architecture automates transfer of analyzer quality-control data into centralized software, reducing manual transcription. The company's broad installed laboratory presence supports Plasma-based Control, Serum-based Control, Whole Blood-based Control, and digital QC applications across Hospitals and Laboratory customers.

Bio-Techne: Bio-Techne is estimated to hold approximately 10-13% competitive market share among major supplied participants, supported by controls spanning hematology, clinical chemistry, immunodiagnostics, blood gas, urine, body fluids, and molecular diagnostics. Its molecular-control portfolio includes stabilized RNA and DNA materials that can remain viable for approximately 36 months under selected frozen-storage conditions. The company also provides custom control formats ranging from single-use vials to high-volume manufacturing configurations, supporting Laboratory, Hospitals, Research Institutes and Academics, and diagnostic developers.

Investment Analysis

Investment in the In Vitro Diagnostics (IVD) Quality Control Market increasingly targets digital QC platforms, molecular controls, stable liquid formulations, automated data transfer, custom-control manufacturing, and laboratory connectivity. Laboratory and Hospitals together represent approximately 77% of market demand, making interoperability with diagnostic instruments an important investment priority. QC software can reduce manual result entry, automate statistical analysis, and allow centralized quality teams to monitor many instruments simultaneously. Informatics launched during 2025 increasingly integrated real-time monitoring with automated verification and simplified rule creation, demonstrating how quality-control investment is moving beyond physical control materials toward combined consumable and software ecosystems.

Molecular diagnostics represents another major investment area because new assays require appropriate extraction and amplification controls. Stabilized RNA and DNA materials are being manufactured under ISO 13485 and current good manufacturing practice environments to improve regulatory readiness. Automation is expanding in parallel. Qiagen N.V. outlined 3 automated sample-preparation instrument launches across 2025 and 2026, including systems targeted at both high- and low-throughput laboratories. Existing automated platforms have surpassed approximately 3,300 cumulative placements, creating an expanding installed base requiring quality assurance and standardized control materials. Through 2035, investment is expected to focus across at least 9 areas including control formulation, molecular stabilization, software analytics, analyzer connectivity, customized manufacturing, peer-group databases, automation, calibration verification, and regulatory compliance.

New Product Development

New Product Development in the In Vitro Diagnostics (IVD) Quality Control Market increasingly focuses on liquid-stable controls, multi-analyte formulations, molecular full-process controls, longer shelf life, platform-independent materials, and automated statistical interpretation. Liquid-ready controls reduce preparation steps and can minimize operator variation compared with products requiring reconstitution. Multi-level products typically offer 2 or 3 concentrations across clinically relevant ranges, while multi-analyte serum formulations allow laboratories to monitor numerous tests from a single vial. Molecular-control development is becoming particularly important because stabilized virus-like particles containing RNA or DNA can monitor the complete workflow from extraction through detection. Certain products can be heat-lysed at approximately 75 degrees Celsius for 3-5 minutes when used as direct positive controls.

Digital quality-control development is also accelerating. New informatics systems are designed to monitor instrument and assay performance continuously and can support multiple analyzer connections across laboratories. Automated data capture removes manual transcription, while configurable rules identify trends and deviations earlier. Six Sigma metrics are increasingly incorporated to help laboratories determine whether an assay requires intensive or reduced QC frequency. Product development through 2035 will increasingly compete across at least 10 characteristics including stability, commutability, concentration range, multi-analyte coverage, ease of use, platform independence, connectivity, statistical analytics, traceability, and compatibility with automated laboratory workflows.

Five Recent Developments

• January 2026: Qiagen N.V. outlined 2026 priorities including new automation launches and regulatory milestones across 5 strategic growth pillars, expanding the installed laboratory base requiring standardized quality monitoring.
• November 2025: Bio-Techne expanded visibility of its third-party clinical controls across 5 major disciplines including hematology, clinical chemistry, immunoassay, blood gas, and molecular diagnostics.
• August 2025: Quidel Corp. expanded diagnostic access through a certified analyzer program designed for physician-office laboratories, clinics, and smaller hospitals with fewer than 100 beds.
• July 2025: Advanced laboratory quality programs increased adoption of Six Sigma metrics to evaluate analytical performance, optimize QC rules, and support data-driven decisions across high-throughput diagnostic environments.
• March 2025: Quidel Corp. introduced laboratory informatics offering real-time QC monitoring, automated result verification, multi-instrument connectivity, and support for unlimited concurrent users across connected diagnostic environments.

Report Coverage

The In Vitro Diagnostics (IVD) Quality Control Market report covers the 2026-2035 forecast period using the stated 2025 baseline and evaluates the supplied Product Types of Plasma-based Control, Serum-based Control, and Whole Blood-based Control. Estimated Product Type shares are approximately 33%, 44%, and 23%, respectively. Application coverage includes Laboratory at approximately 43%, Hospitals at 34%, Research Institutes and Academics at 15%, and Others at 8%. The analysis evaluates internal quality control, third-party controls, calibration verification, molecular controls, clinical chemistry, immunoassay, hematology, blood gas, peer-group comparison, risk-based QC, Six Sigma, Levey-Jennings monitoring, automated data capture, reagent-lot verification, proficiency testing, and laboratory accreditation. Modern molecular control materials can remain stable for approximately 36 months under selected frozen conditions, while quantitative method verification protocols can be completed in as few as 5 days under established laboratory procedures.

Regional coverage includes North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa, with estimated market shares of approximately 39%, 27%, 25%, 5%, and 4%, respectively. Competitive coverage includes all 5 supplied companies: Quidel Corp., Bio-Techne, Alere, Inc., Qiagen N.V., and Bio-Rad Laboratories, Inc. The report evaluates how automated platforms with more than 3,300 cumulative installations, multi-instrument QC connectivity, 2-3 level control systems, molecular materials with approximately 36-month frozen stability, risk-based quality planning, automated verification, custom controls, and decentralized testing will influence the In Vitro Diagnostics (IVD) Quality Control Market through 2035. Serum-based Control remains the leading Product Type with approximately 44% market share, while Laboratory remains the dominant Application with approximately 43% of market demand.